C-src Inhibitor Targets Alpha-Synuclein Aggregation in Synucleinopathy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for Parkinson's disease and other synucleinopathies are limited to symptom alleviation, and there is a lack of understanding regarding the specific receptors and mechanisms involved in the migration and aggregation of alpha-synuclein, which are key factors in the pathogenesis of these diseases.
Innovation Solution
The development of a composition that inhibits the aggregation and/or migration of alpha-synuclein by targeting the expression or activation of the c-src protein, which is involved in the intracellular signaling process and the denaturation of alpha-synuclein into aggregates.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of operation
If conservative treatment is used to alleviate symptoms, then patient comfort is improved, but the underlying cause of the disease is not eliminated
Solution Approach 1:
The invention extracts and targets the specific molecular mechanism (c-src protein) that drives alpha-synuclein aggregation and migration. By isolating this key pathological factor and developing inhibitors specifically against it, the treatment addresses the root cause rather than just symptoms, while maintaining pharmacological precision to ensure safety and efficacy.
2Reliability
If alpha-synuclein aggregation is targeted, then disease progression is slowed, but the specific receptors and mechanisms remain unknown
Solution Approach 1:
The invention incorporates feedback mechanisms by using c-src expression levels and alpha-synuclein aggregation markers as biomarkers to monitor treatment response. This allows for adjustment of therapy based on actual disease progression, ensuring effective control while the ongoing research continues to elucidate the complete molecular mechanisms involved.
3Reliability
If c-src inhibition is used to prevent alpha-synuclein migration, then aggregation is reduced, but potential off-target effects may occur
Solution Approach 1:
The invention applies local quality by designing c-src inhibitors with high specificity for the pathological context of alpha-synuclein aggregation. The treatment is targeted to affect primarily the abnormal c-src activity associated with synucleinopathy, while sparing normal physiological functions of c-src in healthy cells, thereby reducing off-target effects.
Data Source
AI summary
A composition including a substance that inhibits an expression or activity of c-src and its use in inhibiting aggregation and/or migration of α-syn are disclosed. The composition may be a pharmaceutical composition and can be used for preventing or treating synucleinopathy. The substance can inhibit the signal transduction induced by α-syn migrating to adjacent cells, thus mitigating the cytotoxic influence of α-syn on the adjacent cells; and can inhibit the denaturation of monomeric α-syn into aggregated α-syn, which may be a major cause of synucleinopathy, and thus, can be beneficially used as a therapeutic agent for synucleinopathy.